Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Ovarian Cancer Resource Center

News
Integrated Clinical Pathway Dashboard Enhances Germline Testing in Patients With Ovarian Cancer
03/19/2024

Brandon Twyford

Brandon Twyford
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and...
03/19/2024
Journal of Clinical Pathways
News
The Cost-Effectiveness of Prevention Strategies for Individuals Who Carry CSGs for Ovarian Cancer and Breast Cancer
03/18/2024

Grace Taylor

Grace Taylor
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and...
03/18/2024
Journal of Clinical Pathways
News
Individualized Starting Dose of Niraparib in Ovarian Cancer Reduces Hematologic Adverse Event Costs
03/18/2024

Brandon Twyford

Brandon Twyford
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the...
03/18/2024
Journal of Clinical Pathways
News
AI Machine Learning Models Accurately Predict Ovarian Cancer Recurrence and Platinum Sensitivity
03/18/2024
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine...
03/18/2024
Journal of Clinical Pathways
Conference Coverage
Upifitamab Rilsodoti Did Not Improve Response Rate for Patients With Previously Treated Platinum-Resistant Ovarian Cancer
03/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the...
03/16/2024
Oncology
From Oncology
News
Safety and Efficacy Analysis of Lurbinectedin in Patients With Advanced Ovarian Tumors
01/16/2024

By Emry Lloyd

By Emry Lloyd
An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.
An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.
An analysis conducted by...
01/16/2024
Journal of Clinical Pathways
News
Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer
12/19/2023

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the...
12/19/2023
Oncology
From Oncology
Research Reports
Treatment Duration, Adherence, Interruptions, and Discontinuations Associated With Maintenance Regimens for Recurrent Ovarian Cancer
06/05/2023
Emma L. Barber, MD
Allison M. Saiz, MD
Nicole M. Engel-Nitz, PhD
Scott H. Bunner, MPH
Katrine L. Wallace, PhD
Emma L. Barber, MD, and colleagues investigate current and real-world practice patterns for patients receiving maintenance therapy for recurrent ovarian cancer after second-line chemotherapy.
Emma L. Barber, MD, and colleagues investigate current and real-world practice patterns for patients receiving maintenance therapy for recurrent ovarian cancer after second-line chemotherapy.
Emma L. Barber, MD, and...
06/05/2023
Journal of Clinical Pathways
News
Minimally Invasive Surgery vs Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy
08/17/2022

Yvette C Terrie

Yvette C Terrie
Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.
Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.
Complete cytoreductive surgery...
08/17/2022
Journal of Clinical Pathways
News
Anti-mesothelin CAR-T Immunotherapy Could be Effective in Ovarian Cancer
08/16/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.
Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.
Findings from a recent study...
08/16/2022
Journal of Clinical Pathways
News
Real-World Management of Mucinous Ovarian Cancer
08/11/2022

Yvette C Terrie

Yvette C Terrie
Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.
Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.
Construction of a nomogram...
08/11/2022
Journal of Clinical Pathways

Expert Insights

Winston Wong, PharmD
Videos
Pathways Disruptors in Ovarian Cancer
06/22/2022
Winston Wong, PharmD, discusses the ATHENA-MONO trial, an international, randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib as first-line maintenance treatment across a diverse patient population with newly...
Winston Wong, PharmD, discusses the ATHENA-MONO trial, an international, randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib as first-line maintenance treatment across a diverse patient population with newly...
Winston Wong, PharmD, discusses...
06/22/2022
Journal of Clinical Pathways
Eloise Chapman-Davis, MD
Videos
Identifying Disparities in Genetic Testing Among Patients With Ovarian Cancer
06/14/2022
Eloise Chapman-Davis, MD, discusses her research on existing disparities in genetic counseling in ovarian cancer, finding that less than half of patients with newly diagnosed breast or ovarian cancer receive germline testing, despite NCCN...
Eloise Chapman-Davis, MD, discusses her research on existing disparities in genetic counseling in ovarian cancer, finding that less than half of patients with newly diagnosed breast or ovarian cancer receive germline testing, despite NCCN...
Eloise Chapman-Davis, MD,...
06/14/2022
Journal of Clinical Pathways
Jinan Liu, MD, PhD, GlaxoSmithKline
Videos
Real-World Study on Niraparib as First Line Maintenance for Newly Diagnosed Advanced Ovarian Cancer
05/03/2022
Jinan Liu, MD, PhD, evaluated dose assignment and uptake of the individualized starting dose among US patients with ovarian cancer who were receiving niraparib as first-line maintenance therapy, using real-world data.
Jinan Liu, MD, PhD, evaluated dose assignment and uptake of the individualized starting dose among US patients with ovarian cancer who were receiving niraparib as first-line maintenance therapy, using real-world data.
Jinan Liu, MD, PhD, evaluated...
05/03/2022
Journal of Clinical Pathways
Jinan Liu, MD, PhD
Videos
Real-World Use of PARP Inhibitor for First-line Maintenance in Newly Diagnosed Ovarian Cancer
05/02/2022
Jinan Liu, MD, PhD describes the use of first-line maintenance therapies among patients with ovarian cancer and examines predictors of first-line poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor maintenance therapy use.
Jinan Liu, MD, PhD describes the use of first-line maintenance therapies among patients with ovarian cancer and examines predictors of first-line poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor maintenance therapy use.
Jinan Liu, MD, PhD describes the...
05/02/2022
Journal of Clinical Pathways
Sarah Temkin, MD
Videos
Survey Aims to Inform Quality Improvement Initiatives in Ovarian Cancer Care Programs
11/01/2021
Sarah Temkin, MD, discusses a national survey of ovarian cancer care programs in the United States, identifying the needs of patients and informing quality improvement initiatives for these programs.
Sarah Temkin, MD, discusses a national survey of ovarian cancer care programs in the United States, identifying the needs of patients and informing quality improvement initiatives for these programs.
Sarah Temkin, MD, discusses a...
11/01/2021
Journal of Clinical Pathways
Jinan Liu, MD, PhD
Videos
Real-World Maintenance Therapy Use in Newly Diagnosed Ovarian Cancer
07/24/2021
Jinan Liu, MD, discusses results from a real-world study exploring patterns and predictors of maintenance therapy use among patients with newly diagnosed ovarian cancer.
Jinan Liu, MD, discusses results from a real-world study exploring patterns and predictors of maintenance therapy use among patients with newly diagnosed ovarian cancer.
Jinan Liu, MD, discusses results...
07/24/2021
Journal of Clinical Pathways
Katrine Wallace, PhD, MS
Videos
Real-World Utilization of Second-Line Maintenance Therapy for Advanced Ovarian Cancer
07/19/2021
Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.
Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.
Katrine Wallace, PhD, MS,...
07/19/2021
Journal of Clinical Pathways
Videos
Rucaparib vs Chemotherapy for Platinum-Sensitive Patients With Advanced Ovarian Cancer
06/23/2021
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses...
06/23/2021
Journal of Clinical Pathways
Biomarker-Guided First-Line Maintenance Therapy in Advanced Ovarian Cancer: Real-World Outcomes and Cost
Videos
Biomarker-Guided First-Line Maintenance Therapy in Advanced Ovarian Cancer: Real-World Outcomes and Cost
04/27/2021
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Daniel Simmons, PharmD, MS,...
04/27/2021
Journal of Clinical Pathways
Maintenance Olaparib Demonstrates Long-Term Benefit in BRCA-Mutated Ovarian Cancer
Videos
Maintenance Olaparib Demonstrates Long-Term Benefit in BRCA-Mutated Ovarian Cancer
04/21/2021
04/21/2021
Journal of Clinical Pathways
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 1)
05/06/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part...
05/06/2024
Cancer Care Business Exchange
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Interview
Venetoclax Plus Ibrutinib Combination Therapy for Treating Patients With CLL With Resistance Mutations
04/19/2024

Featuring Kerry Rogers, MD, The Ohio State University

Featuring Kerry Rogers, MD, The Ohio ...
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State...
04/19/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Robert Stillman, MA, RN
Videos
Best Practices in Care Team Communication Technology: Updates From NCCN 2024
04/06/2024

Featuring Robert Stillman, MA, RN

Featuring Robert Stillman, MA, RN ...
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN,...
04/06/2024
Journal of Clinical Pathways

Newsfeed

News
Integrated Clinical Pathway Dashboard Enhances Germline Testing in Patients With Ovarian Cancer
03/19/2024

Brandon Twyford

Brandon Twyford
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and...
03/19/2024
Journal of Clinical Pathways
News
The Cost-Effectiveness of Prevention Strategies for Individuals Who Carry CSGs for Ovarian Cancer and Breast Cancer
03/18/2024

Grace Taylor

Grace Taylor
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and...
03/18/2024
Journal of Clinical Pathways
News
Individualized Starting Dose of Niraparib in Ovarian Cancer Reduces Hematologic Adverse Event Costs
03/18/2024

Brandon Twyford

Brandon Twyford
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the...
03/18/2024
Journal of Clinical Pathways
News
AI Machine Learning Models Accurately Predict Ovarian Cancer Recurrence and Platinum Sensitivity
03/18/2024
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine...
03/18/2024
Journal of Clinical Pathways
Conference Coverage
Upifitamab Rilsodoti Did Not Improve Response Rate for Patients With Previously Treated Platinum-Resistant Ovarian Cancer
03/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the...
03/16/2024
Oncology
News
Safety and Efficacy Analysis of Lurbinectedin in Patients With Advanced Ovarian Tumors
01/16/2024

By Emry Lloyd

By Emry Lloyd
An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.
An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.
An analysis conducted by...
01/16/2024
Journal of Clinical Pathways
News
Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer
12/19/2023

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the...
12/19/2023
Oncology
News
Minimally Invasive Surgery vs Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy
08/17/2022

Yvette C Terrie

Yvette C Terrie
Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.
Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.
Complete cytoreductive surgery...
08/17/2022
Journal of Clinical Pathways
News
Anti-mesothelin CAR-T Immunotherapy Could be Effective in Ovarian Cancer
08/16/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.
Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.
Findings from a recent study...
08/16/2022
Journal of Clinical Pathways
News
Real-World Management of Mucinous Ovarian Cancer
08/11/2022

Yvette C Terrie

Yvette C Terrie
Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.
Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.
Construction of a nomogram...
08/11/2022
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
04/11/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
04/11/2024
Journal of Clinical Pathways
AI
News
The Potential for AI in Oncology
04/11/2024
Grace Taylor, MS, MA
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay...
04/11/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology

Interactive Features

Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Opportunistic Salpingectomy for Ovarian Cancer Prevention
02/24/2022
True or False: Opportunistic salpingectomy at the time of elective cholecystectomy is not a cost-effective strategy to prevent ovarian cancer among average risk women.
True or False: Opportunistic salpingectomy at the time of elective cholecystectomy is not a cost-effective strategy to prevent ovarian cancer among average risk women.
True or False: Opportunistic...
02/24/2022
Journal of Clinical Pathways
Quiz
Quiz: PARP Inhibitors in Patients With Epithelial Ovarian Cancer
12/14/2021
True or False: Findings from a study assessing patients’ and oncologists’ preferences for second-line PARP inhibitor maintenance in epithelial ovarian cancer suggest that the PFS gains are worth the toxicity risk.
True or False: Findings from a study assessing patients’ and oncologists’ preferences for second-line PARP inhibitor maintenance in epithelial ovarian cancer suggest that the PFS gains are worth the toxicity risk.
True or False: Findings from a...
12/14/2021
Journal of Clinical Pathways
Quiz
Quiz: Differences Between Available PARP Inhibitors for Ovarian Cancer
12/08/2021
True or False: There are differences between available PARP inhibitors in the risk of experiencing a clinical event of interest, likelihood of dose modifications, ability to receive continuous therapy, health care resource utilization, and...
True or False: There are differences between available PARP inhibitors in the risk of experiencing a clinical event of interest, likelihood of dose modifications, ability to receive continuous therapy, health care resource utilization, and...
True or False: There are...
12/08/2021
Journal of Clinical Pathways
Quiz
Quiz: Olaparib Maintenance for Ovarian Cancer
10/06/2021
True or False: Olaparib maintenance is both safe and effective for the treatment of BRCA-mutated recurrent ovarian cancer.
True or False: Olaparib maintenance is both safe and effective for the treatment of BRCA-mutated recurrent ovarian cancer.
True or False: Olaparib...
10/06/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Olaparib vs Niraparib for the Treatment of Ovarian Cancer
09/24/2021
True or False: Olaparib is more cost-effective than niraparib for maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.
True or False: Olaparib is more cost-effective than niraparib for maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.
True or False: Olaparib is more...
09/24/2021
Journal of Clinical Pathways
Quiz
Quiz: First-Line Maintenance Therapy for Ovarian Cancer
08/05/2021
True or False: First-line maintenance therapy use for ovarian cancer has decreased over time, particularly among patients with biomarker guidance.
True or False: First-line maintenance therapy use for ovarian cancer has decreased over time, particularly among patients with biomarker guidance.
True or False: First-line...
08/05/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of VTE Prophylaxis for Ovarian Cancer
07/27/2021
True or False: Venous thromboembolism prophylaxis with direct oral anticoagulants during neoadjuvant chemotherapy for ovarian cancer is more costly but more effective than no therapy.
True or False: Venous thromboembolism prophylaxis with direct oral anticoagulants during neoadjuvant chemotherapy for ovarian cancer is more costly but more effective than no therapy.
True or False: Venous...
07/27/2021
Journal of Clinical Pathways
Quiz
Quiz: Is First-Line Niraparib Maintenance Cost-Effective for Patients With Advanced Ovarian Cancer?
04/16/2021
04/16/2021
Journal of Clinical Pathways
Quiz
Quiz: How Can We Optimize Genetic Testing for Breast and Ovarian Cancer?
03/17/2021
03/17/2021
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Special Reports

Overview of the Updated NCCN Guidelines on Ovarian Cancer
Special Report
Overview of the Updated NCCN Guidelines on Ovarian Cancer
06/17/2020
While ovarian cancer is the second most common gynecologic cancer in the United States, behind uterine cancer,1 it is the top gynecologic cancer in mortality.2 In 2020, an estimated 21,750 new cases of ovarian cancer...
While ovarian cancer is the second most common gynecologic cancer in the United States, behind uterine cancer,1 it is the top gynecologic cancer in mortality.2 In 2020, an estimated 21,750 new cases of ovarian cancer...
While...
06/17/2020
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement